CARDENE SR labels and packaging: Difference between revisions

Revision as of 16:24, 20 February 2014

Nicardipine
CARDENE I.V.^® FDA Package Insert
Indications and Usage
Dosage and Administration
Dosage Forms and Strengths
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
Clinical Studies
How Supplied/Storage and Handling
Labels and Packaging
CARDENE SR ^® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Labels and Packaging

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: :Abdurahman Khalil, M.D. [2]

For patient information about Nicardipine, click here. U.S. Patent Nos. 4,940,556 and 5,198,226

Cardene® is a registered trademark of EKR Therapeutics, Inc.

Marketed by:

EKR Therapeutics, Inc. Bedminster, NJ 07921

Revised: June 2010 02-2440-EX-00

Printed in USA

Package Label - Principal Display Panel – Cardene SR 30 mg

Package Label - Principal Display Panel – Cardene SR 45 mg

Package Label - Principal Display Panel – Cardene SR 60 mg

@@ Line 37: / Line 37: @@
 |}
+<ref> {{cite web | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=ce141ca0-d734-11df-8537-0002a5d5c51b | title = CARDENE SR (nicardipine hydrochloride) capsule, extended release [EKR Therapeutics] | accessdate =}}</ref>
+==References==
 {{Reflist|2}}
 [[Category:Cardiovascular Drugs]]
 [[Category:Drugs]]